MARK HOLLINGSWORTH: Open Payments
NPI 1871787549 · WILMINGTON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,245 in 115 payments from 21 companies in 2025. Trend: 2023 $1,319 · 2024 $1,509 · 2025 $2,245
Food & beverage: $2,245
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 16 | $458 |
| ABBVIE INC. | 17 | $239 |
| Corcept Therapeutics | 11 | $237 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $188 |
| GlaxoSmithKline, LLC. | 11 | $176 |
| Vanda Pharmaceuticals Inc. | 7 | $142 |
| Lilly USA, LLC | 10 | $136 |
| Novo Nordisk Inc | 7 | $125 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $97 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $93 |
Products named: BREZTRI, Korlym, CAPLYTA, TRELEGY ELLIPTA, VRAYLAR, MOUNJARO, HETLIOZ, Kerendia.
Industry payments across NC — which companies pay providers there.
